Entera Current Ratio vs Cost of Revenue Analysis
ENTX Stock | USD 2.05 0.06 3.02% |
Entera Bio financial indicator trend analysis is much more than just examining Entera Bio latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Entera Bio is a good investment. Please check the relationship between Entera Bio Current Ratio and its Cost Of Revenue accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entera Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Entera Stock please use our How to Invest in Entera Bio guide.
Current Ratio vs Cost Of Revenue
Current Ratio vs Cost of Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Entera Bio Current Ratio account and Cost of Revenue. At this time, the significance of the direction appears to have very week relationship.
The correlation between Entera Bio's Current Ratio and Cost of Revenue is 0.29. Overlapping area represents the amount of variation of Current Ratio that can explain the historical movement of Cost of Revenue in the same time period over historical financial statements of Entera Bio, assuming nothing else is changed. The correlation between historical values of Entera Bio's Current Ratio and Cost of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Ratio of Entera Bio are associated (or correlated) with its Cost of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost of Revenue has no effect on the direction of Current Ratio i.e., Entera Bio's Current Ratio and Cost of Revenue go up and down completely randomly.
Correlation Coefficient | 0.29 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Current Ratio
A liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities.Cost Of Revenue
Cost of Revenue is found on Entera Bio income statement and represents the costs associated with goods and services Entera Bio provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most indicators from Entera Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Entera Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entera Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Entera Stock please use our How to Invest in Entera Bio guide.At this time, Entera Bio's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 51.15 in 2024, despite the fact that Tax Provision is likely to grow to (16.1 K).
2023 | 2024 (projected) | Interest Income | 854.5K | 696.3K | Reconciled Depreciation | 59K | 84.1K |
Entera Bio fundamental ratios Correlations
Click cells to compare fundamentals
Entera Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Entera Bio fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 16.7M | 10.3M | 26.0M | 13.1M | 11.8M | 13.9M | |
Other Current Liab | 3.8M | (189K) | 2.8M | (134K) | 874K | 1.3M | |
Total Current Liabilities | 4.6M | 3.3M | 3.2M | 1.3M | 1.1M | 1.0M | |
Total Stockholder Equity | 11.9M | 6.7M | 22.6M | 11.8M | 10.4M | 10.9M | |
Net Tangible Assets | 11.3M | 6.1M | 22.6M | 11.8M | 13.5M | 14.2M | |
Property Plant And Equipment Net | 462K | 192K | 395K | 139K | 488K | 305.4K | |
Net Debt | (14.9M) | (8.2M) | (24.6M) | (12.2M) | (10.6M) | (11.2M) | |
Retained Earnings | (62.9M) | (72.9M) | (82.4M) | (95.5M) | (104.4M) | (99.2M) | |
Accounts Payable | 334K | 1.8M | 166K | 1.3M | 83K | 78.9K | |
Cash | 15.2M | 8.6M | 24.9M | 12.3M | 11.0M | 11.8M | |
Non Current Assets Total | 1.1M | 1.2M | 658K | 278K | 508K | 631.1K | |
Cash And Short Term Investments | 15.2M | 8.6M | 24.9M | 12.3M | 11.0M | 12.3M | |
Common Stock Shares Outstanding | 12.1M | 18.4M | 26.1M | 28.8M | 29.0M | 19.3M | |
Liabilities And Stockholders Equity | 16.7M | 10.3M | 26.0M | 13.1M | 11.8M | 13.9M | |
Non Current Liabilities Total | 192K | 324K | 261K | 32K | 288K | 273.6K | |
Other Current Assets | 97K | 93K | 254K | 294K | 238K | 188.5K | |
Other Stockholder Equity | 63.4M | 70.6M | 105.0M | 107.2M | 114.7M | 63.3M | |
Total Liab | 4.8M | 3.6M | 3.4M | 1.4M | 1.4M | 1.3M | |
Property Plant And Equipment Gross | 462K | 548K | 395K | 229K | 488K | 359.9K | |
Total Current Assets | 15.6M | 9.1M | 25.3M | 12.8M | 11.3M | 13.0M | |
Accumulated Other Comprehensive Income | 13.1M | 11.4M | 9.0M | 41K | 36.9K | 35.1K | |
Property Plant Equipment | 462K | 548K | 395K | 229K | 263.4K | 337.8K | |
Non Currrent Assets Other | (1.1M) | 356K | 46K | 96K | 6K | 5.7K | |
Net Invested Capital | 11.9M | 6.7M | 22.6M | 11.8M | 10.4M | 7.2M | |
Net Working Capital | 11.0M | 5.8M | 22.2M | 11.5M | 10.2M | 12.9M | |
Current Deferred Revenue | 267K | 1.4M | 15K | 43K | 38.7K | 36.8K |
Pair Trading with Entera Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entera Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entera Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with Entera Stock
0.67 | ELYM | Eliem Therapeutics | PairCorr |
Moving against Entera Stock
0.74 | PCRX | Pacira Pharmaceuticals Financial Report 1st of May 2024 | PairCorr |
0.71 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
0.66 | MGTX | MeiraGTx Holdings PLC Financial Report 9th of May 2024 | PairCorr |
0.59 | PFE | Pfizer Inc Aggressive Push | PairCorr |
0.56 | PCVX | VaxcyteInc Financial Report 13th of May 2024 | PairCorr |
The ability to find closely correlated positions to Entera Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entera Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entera Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entera Bio to buy it.
The correlation of Entera Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entera Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entera Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entera Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entera Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Entera Stock please use our How to Invest in Entera Bio guide.You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Entera Stock analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Transaction History View history of all your transactions and understand their impact on performance | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is Entera Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entera Bio. If investors know Entera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entera Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.31) | Quarterly Revenue Growth (0.92) | Return On Assets (0.45) | Return On Equity (0.80) |
The market value of Entera Bio is measured differently than its book value, which is the value of Entera that is recorded on the company's balance sheet. Investors also form their own opinion of Entera Bio's value that differs from its market value or its book value, called intrinsic value, which is Entera Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entera Bio's market value can be influenced by many factors that don't directly affect Entera Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entera Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Entera Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entera Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.